REMAP-CAP (A Randomized, Embedded, Multifactorial, Adaptive Platform Trial for Community-Acquired Pneumonia) was developed to test treatments for severe pneumonia both in non-pandemic and pandemic settings. In February 2020, REMAP-CAP rapidly pivoted to its pandemic mode (known as the REMAP-COVID sub-study in the U.S.), as per its original intent, to incorporate additional potential treatment regimens specifically targeting COVID-19 and to expand enrollment to COVID-19 patients. The main objective of REMAP-CAP: COVID is to reduce mortality and morbidity in patients hospitalized with COVID-19 infection.
Global Coalition for Adaptive Research (GCAR) serves at the US Sponsor for the REMAP-COVID trial alongside University of Pittsburgh, the US Regional Coordinating Center. The Immunomodulation Domain (REMAP-COVID IM-2 DSA) began with the evaluation of multiple drugs.
Currently in the U.S., 2 domains for the REMAP-CAP: COVID trial are active: the Immune Modulation 2 Domain (REMAP-COVID IM-2 DSA) and the Vitamin C Domain (REMAP-COVID Vit-C DSA). Patients were initially enrolled in these domains at the first active site, University of Pittsburgh, in October 2020. More than 15 sites in the US are now recruiting.
For more information regarding the trial please visit:
Questions, please email firstname.lastname@example.org